0000899243-18-024561.txt : 20180914
0000899243-18-024561.hdr.sgml : 20180914
20180914180041
ACCESSION NUMBER: 0000899243-18-024561
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180912
FILED AS OF DATE: 20180914
DATE AS OF CHANGE: 20180914
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ODONNELL FRANCIS E JR
CENTRAL INDEX KEY: 0001066040
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31361
FILM NUMBER: 181072039
MAIL ADDRESS:
STREET 1: BIODELIVERY SCIENCES INTERNATIONAL, INC
STREET 2: 4131 PARKLAKE AVENUE, SUITE #225
CITY: RALEIGH
STATE: NC
ZIP: 27612
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIODELIVERY SCIENCES INTERNATIONAL INC
CENTRAL INDEX KEY: 0001103021
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 352089858
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4131 PARKLAKE AVENUE
STREET 2: SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
BUSINESS PHONE: 919 582 9050
MAIL ADDRESS:
STREET 1: 4131 PARKLAKE AVENUE
STREET 2: SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
FORMER COMPANY:
FORMER CONFORMED NAME: MAS ACQUISITION XXIII CORP
DATE OF NAME CHANGE: 20000111
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-09-12
0
0001103021
BIODELIVERY SCIENCES INTERNATIONAL INC
BDSI
0001066040
ODONNELL FRANCIS E JR
C/O BIODELIVERY SCIENCES INTL, INC.,
4131 PARKLAKE AVENUE, SUITE 225
RALEIGH
NC
27612
1
0
0
0
Common Stock
2018-09-12
4
M
0
133333
0.00
A
520482
D
Common Stock
2018-09-12
4
S
0
66667
2.83
D
453815
D
Common Stock
2018-09-13
4
A
0
6806
0.00
A
460621
D
Common Stock
2018-09-13
4
M
0
46000
0.00
A
506621
D
Common Stock
2018-09-13
4
M
0
62500
0.00
A
569121
D
Common Stock
2018-09-13
4
A
0
53438
0.00
A
622559
D
Common Stock
2018-09-13
4
S
0
84372
2.84
D
538187
D
Restricted Stock Units
0.00
2018-09-12
4
M
0
133333
0.00
D
2018-09-12
2018-09-12
Common Stock
133333
0
D
Restricted Stock Units
0.00
2018-09-13
4
A
0
6806
0.00
D
2018-09-13
2018-09-13
Common Stock
6806
0
D
Restricted Stock Units
0.00
2018-09-13
4
M
0
46000
0.00
D
2018-09-13
2019-03-01
Common Stock
46000
46000
D
Restricted Stock Units
0.00
2018-09-13
4
M
0
62500
0.00
D
2018-09-13
2020-02-06
Common Stock
62500
125000
D
Restricted Stock Units
0.00
2018-09-13
4
A
0
53438
0.00
D
2018-09-13
2018-09-13
Common Stock
53438
0
D
The shares of common stock were acquired by the Reporting Person as a result of the vesting of 133,333 of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 23, 2015 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on September 12, 2018.
The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs.
On September 12, 2018, the Reporting Person sold an aggregate of 66,667 shares of the Issuer's Common Stock at a weighted average price of $2.83 per share. The highest sale price for the Common Stock was $2.85 per share and the lowest sale price was $2.80 per share.
The shares of common stock were acquired by the Reporting Person in connection with the vesting of RSUs granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. Pursuant to a deferral, these RSUs vested on September 13, 2018.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. Pursuant to a deferral, the remainder of the RSUs under this grant will vest on March 1, 2019.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 6, 2017 under the Plan. Pursuant to a deferral, these RSUs vested on September 13, 2018. The remainder of the RSUs under this grant will vest in equal portions after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the performance-based RSUs ("Performance RSUs") granted to the Reporting Person on February 6, 2017 under the Plan subject to certain performance measures. The remainder of the Performance RSUs under this grant will vest, in equal amounts, but subject to certain performance measures, after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020.
On September 13, 2018, the Reporting Person sold an aggregate of 84,372 shares of the Issuer's Common Stock at a weighted average price of $2.84 per share. The highest sale price for the Common Stock was $2.90 per share and the lowest sale price was $2.90 per share.
The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
/s/ Francis E. O'Donnell Jr.
2018-09-14